Virtual Library
Start Your Search
G.Z. Dal Molin
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-019 - Treatment and Clinical Evolution of a Cohort of 105 EGFR Mutant Patients from a Single Institution (ID 3162)
09:30 - 09:30 | Author(s): G.Z. Dal Molin
- Abstract
Background:
Lung cancer is among the most common malignancies in Brazil. The use of tyrosine-kinase inhibitors (TKI) is nowadays a solidIy stablished treatment strategy for EGFR mutaion bearing NSCLC metastatic tumors. In this study we describe the clinical evolution of a cohort of 115 EGFR-mutant NSCLC patients from a single brazilian institution.
Methods:
We describe a retrospective cohort of 115 consecutive patients bearing metastatic EGFR mutated NSCLC, treated at A.C.. Camargo Cancer Center, Sao Paulo, from August/2010 to December/2014. Patients were older than 18y and had to have a histologically confirmed NSCLC dianosis. Clinical and pathological data was extracted from their eletronical medical charts. Chi-square statistics, or Fisher’s exact test when appropriate, was used to compare proportions among groups, Kaplan-Meier method was used for survival analysis and log-rank’s test was performed to compare survival curves.
Results:
Median age was 64y, 62% of patients were female, 94% had adenocarcinoma and 22% were smokers/former smokers. Data about treatment and survival was available for 85/115 patients. Eighty eight percent (75/85) of them were metastatic at diagnosis, of whom 52% (39/75) received a TKI in first line, 24% (18/75) in second line, 5% (4/75) in third/later lines and 16% were never treated with a TKI. Median progression free survival (PFS) was 13.9 months (m) for first line TKI and 11.4m for TKI treatment in second line (p=0.028). Median PFS for first line platin-based chemotherapy was 9.6m as compared to 3.1m for platin-based chemotherapy in second line (p=0.001). PFS with TKI treatment was numerically superior but not statistically significant for patients bearing tumors with exon 19 deletions as compared to L858R mutantions (22.9m vs 13.4m, respectively; p=0.42). There was no difference in overal survival (OS) between patients treated with TKI in first or second line. Median OS for patients receiving first line TKI was 36.3m and was not reached for patients that received TKI in second line (p=0.61).
Conclusion:
OS survival was not different for patients bearing EGFR mutated NSCLC tumors treated in first or second line, despite a longer PFS for TKI given as first line therapy.
